Analyses / Whip Count Analysis / 119 · HRES 803 Whip Count Analysis

119-HRES-803 DC Insider Whip Count Analysis

119 · HRES 803 Urging the Director of the Food and Drug Administration to reevaluate the safety of all chemical abortion drugs in light of recent independent studies, and for other purposes.

Bottom line: With Republicans holding a narrow House majority and leadership aligned with anti–abortion-pill messaging, H. Res. 803 is likely to pass if and when the Speaker brings it up, but margin depends on a handful of Biden‑district Republicans (e.g., Lawler, Fitzpatrick) and attendance amid the ongoing shutdown. Expect a largely party‑line vote; committee bottleneck is Energy & Commerce, and floor control rests with Rules and the Speaker. Confidence: moderate. [1]AP News — Republican Mike Johnson reelected House speaker in dramatic floor vote[2]Congress.gov (CRS) — Membership of the 119th Congress: A Profile[3]House Rules Committee (majority) — Chairwoman Foxx Opening Remarks on Rules' Or…[4]House Energy & Commerce Committee (majority) — Chairman Guthrie Announces House…

Published
11 Oct 2025
Updated
11 Oct 2025
Tags
Whipcount · House Simple Resolution · FDA
Unvetted
01 · Section

Breakdown: expected support/opposition

Institutional context: Republicans control the House in the 119th Congress with a slim, shifting margin; Mike Johnson was re‑elected Speaker on January 3, 2025. Floor time is tightly managed through the Rules Committee under Chair Virginia Foxx. Jurisdictionally, a resolution urging FDA action will sit in Energy & Commerce under Chair Brett Guthrie before leadership decides whether to mark it up or go straight to a special rule. [1]AP News — Republican Mike Johnson reelected House speaker in dramatic floor vote[2]Congress.gov (CRS) — Membership of the 119th Congress: A Profile[3]House Rules Committee (majority) — Chairwoman Foxx Opening Remarks on Rules' Or…[4]House Energy & Commerce Committee (majority) — Chairman Guthrie Announces House…

  • Republicans: Broad support. The sponsor bloc and E&C Republicans have been pushing FDA to tighten or revisit mifepristone policies; Senate GOP just pressed HHS/FDA to reevaluate a newly approved generic. Expect most House Republicans to vote yes on a “reevaluate safety” message. [5]Office of Rep. John Rose — Rep. Rose on Supporting End of Abortion Drug By Mail[4]House Energy & Commerce Committee (majority) — Chairman Guthrie Announces House…[6]Office of Sen. Katie Britt — U.S. Senators Katie Britt, Lindsey Graham, Colleag…
  • Democrats: Broad opposition. House Democratic leadership consistently frames medication abortion access as a priority and has backed resolutions affirming access; major medical groups (e.g., ACOG) continue to state mifepristone is safe and oppose added restrictions. Expect near‑uniform Democratic no. [7]Office of House Democratic Leader Hakeem Jeffries — Leader Jeffries: Three Year…[8]Congress.gov — Text – H. Res. 65 (119th): Reaffirming the freedom to decide and…[9]ACOG — Leading Medical Organizations Reaffirm the Safety of Mifepristone
  • Independents/Delegates: No decisive bloc effect expected on a messaging resolution; outcome hinges on a handful of swing‑district Republicans and attendance. [2]Congress.gov (CRS) — Membership of the 119th Congress: A Profile
  • Numbers: With an effective GOP edge in the low‑220s but frequent vacancies/absences, a party‑line rule and passage vote can clear with 217–218 present and voting. Base case: GOP yes in the 210–215 range; Dem yes at or near zero; outcome sensitive to 3–5 Biden‑district GOP defections or missed votes. [2]Congress.gov (CRS) — Membership of the 119th Congress: A Profile
02 · Section

Key legislators (pivotal swing votes)

Focus on Republicans from Biden‑won seats and/or members who have publicly broken with the party on abortion‑pill access.

Member Why pivotal Read on their record/stance
Mike Lawler (R‑NY) Publicly says he fought his own party to maintain access to mifepristone; likely no or abstain on a resolution framed as restricting access. Member site states he “fought his own party to help maintain access to mifepristone.” [10]Office of Rep. Mike Lawler — Women’s Health – Rep. Mike Lawler position page
Brian Fitzpatrick (R‑PA) Has urged caution on advancing restrictive abortion bills; moderate profile in a Biden‑won district; true toss‑up. Said it’s “not wise” to push restrictive abortion bills; local coverage emphasizes his moderate positioning on abortion. [11]North Penn Now — Congressman Fitzpatrick: ‘I Don’t Think It’s Wise’ To Advance…[12]Web search · turn 14 #0
David Valadao (R‑CA) Biden‑district Republican who tends to avoid national‑ban framing; might follow leadership on a narrow “safety review” message; watch attendance. Previously dodged national‑ban questions; emphasized state focus. [13]Web search · turn 15 #1
Don Bacon (R‑NE) Centrist; articulates a state‑centric posture; less likely to oppose a “review” resolution, but could balk if it’s seen as back‑door restriction. States are the “center of gravity” on abortion; swing‑seat risk calculus applies. [13]Web search · turn 15 #1
Diana Harshbarger (R‑TN) E&C vice chair; has led House efforts to reverse Biden‑era mifepristone flexibilities; solid yes and potential caucus whip on this issue. Reintroduced legislation to overturn Biden‑era FDA policy on mifepristone. [14]Web search · turn 18 #4
03 · Section

Leadership influence and procedural dynamics

This is a House‑only simple resolution. Passage hinges on majority leadership’s appetite to run a messaging vote and manage a tight margin.

  • Speaker/majority: Speaker Mike Johnson controls floor timing; he’s pro‑life but has publicly downplayed prospects for a national ban, suggesting leadership will prefer messaging and oversight moves like H. Res. 803. Expect the Speaker to green‑light a floor vote when politically advantageous. [1]AP News — Republican Mike Johnson reelected House speaker in dramatic floor vote[15]The Washington Post — Johnson says he does not see national abortion ban next y…
  • Rules Committee: Chair Virginia Foxx can report a closed rule to expedite floor action and contain amendments; with a narrow majority, leadership typically limits amendment exposure on polarizing social issues. [3]House Rules Committee (majority) — Chairwoman Foxx Opening Remarks on Rules' Or…
  • Committee of referral: Energy & Commerce Chair Brett Guthrie can run a quick markup or allow leadership to bypass via a rule; E&C Republicans have been active on FDA/mifepristone oversight. [4]House Energy & Commerce Committee (majority) — Chairman Guthrie Announces House…
  • Minority leadership: Hakeem Jeffries has anchored the caucus on protecting medication abortion access, making a whipped no vote likely. [7]Office of House Democratic Leader Hakeem Jeffries — Leader Jeffries: Three Year…
  • External pressure: GOP senators’ letter urging HHS/FDA to reevaluate a newly approved generic mifepristone reinforces intra‑party pressure for a House vote; abortion‑rights groups and medical societies will press Democrats to oppose. [6]Office of Sen. Katie Britt — U.S. Senators Katie Britt, Lindsey Graham, Colleag…[9]ACOG — Leading Medical Organizations Reaffirm the Safety of Mifepristone
  • Context/timing risk: The House has been in extended shutdown‑related recess; floor scheduling is fluid. If/when members return, leadership can drop this into a messaging block quickly via a structured rule. [16]AP News — Speaker Johnson keeps House lawmakers away, canceling another week's…
04 · Section

Assessment: likelihood of passage

What will happen, not what should happen.

Estimated GOP yes
210to 215
Estimated Dem yes
0to 3
Overall likelihood to pass if called up
0.65probability (moderate)

Rationale: The issue salience inside the GOP conference is high (sponsor/signer momentum; Senate GOP letter), and the resolution’s text avoids a hard policy ban, making it easier for most Republicans to support. The gavel, Rules, and E&C are aligned. The only real exposure is a handful of Biden‑district Republicans (notably Lawler; Fitzpatrick uncertain) plus attendance during a volatile floor calendar. Net: moderate likelihood of passage on a mostly party‑line vote if leadership brings it up before year‑end. [5]Office of Rep. John Rose — Rep. Rose on Supporting End of Abortion Drug By Mail[6]Office of Sen. Katie Britt — U.S. Senators Katie Britt, Lindsey Graham, Colleag…[3]House Rules Committee (majority) — Chairwoman Foxx Opening Remarks on Rules' Or…[4]House Energy & Commerce Committee (majority) — Chairman Guthrie Announces House…[10]Office of Rep. Mike Lawler — Women’s Health – Rep. Mike Lawler position page[11]North Penn Now — Congressman Fitzpatrick: ‘I Don’t Think It’s Wise’ To Advance…

05 · Section

Sourcing (selected)

Key references underpinning whipcount, leadership control, caucus stances, and the regulatory backdrop.

  • House control, margins, and Speaker election: AP and CRS profile of the 119th; Johnson re‑elected Speaker. [1]AP News — Republican Mike Johnson reelected House speaker in dramatic floor vote[2]Congress.gov (CRS) — Membership of the 119th Congress: A Profile
  • Rules and E&C leadership/jurisdiction: official committee pages confirming Chair Foxx (Rules) and Chair Guthrie (E&C). [3]House Rules Committee (majority) — Chairwoman Foxx Opening Remarks on Rules' Or…[4]House Energy & Commerce Committee (majority) — Chairman Guthrie Announces House…
  • Sponsor/House GOP posture on mifepristone: Rep. John Rose statement opposing mail‑order mifepristone; E&C GOP activity. [5]Office of Rep. John Rose — Rep. Rose on Supporting End of Abortion Drug By Mail[4]House Energy & Commerce Committee (majority) — Chairman Guthrie Announces House…
  • Senate GOP pressure campaign: Letter urging reevaluation of the new generic. [6]Office of Sen. Katie Britt — U.S. Senators Katie Britt, Lindsey Graham, Colleag…
  • Democratic leadership posture: Jeffries remarks backing reproductive freedom/medication abortion access; House Dem access resolution. [7]Office of House Democratic Leader Hakeem Jeffries — Leader Jeffries: Three Year…[8]Congress.gov — Text – H. Res. 65 (119th): Reaffirming the freedom to decide and…
  • Medical community stance: ACOG statements reaffirming mifepristone safety. [9]ACOG — Leading Medical Organizations Reaffirm the Safety of Mifepristone
  • Regulatory backdrop: Reports that FDA approved a new generic mifepristone in early October 2025. [18]Reuters — US FDA approves another generic version of abortion pill
  • Swing‑vote evidence points: Lawler’s public position on mifepristone access; Fitzpatrick’s caution on further restrictions. [10]Office of Rep. Mike Lawler — Women’s Health – Rep. Mike Lawler position page[11]North Penn Now — Congressman Fitzpatrick: ‘I Don’t Think It’s Wise’ To Advance…
  • SCOTUS context on mifepristone (standing, 2024): summary of FDA v. AHM decision. [19]Wired — Supreme Court Upholds Access to Abortion Pill in Unanimous Vote
  • Calendar risk: ongoing shutdown‑related recess affecting House scheduling. [16]AP News — Speaker Johnson keeps House lawmakers away, canceling another week's…
Sources cited
  1. [1] Republican Mike Johnson reelected House speaker in dramatic floor vote AP News
  2. [2] Membership of the 119th Congress: A Profile Congress.gov (CRS)
  3. [3] Chairwoman Foxx Opening Remarks on Rules' Organizational Meeting House Rules Committee (majority)
  4. [4] Chairman Guthrie Announces House Committee on Energy and Commerce Full Committee Organizational Meeting for the 119th Congress House Energy & Commerce Committee (majority)
  5. [5] Rep. Rose on Supporting End of Abortion Drug By Mail Office of Rep. John Rose
  6. [6] U.S. Senators Katie Britt, Lindsey Graham, Colleagues Urge FDA to Reevaluate Generic Abortion Pill Approval Office of Sen. Katie Britt
  7. [7] Leader Jeffries: Three Years Since Dobbs – remarks on reproductive freedom Office of House Democratic Leader Hakeem Jeffries
  8. [8] Text – H. Res. 65 (119th): Reaffirming the freedom to decide and supporting medication abortion access Congress.gov
  9. [9] Leading Medical Organizations Reaffirm the Safety of Mifepristone ACOG
  10. [10] Women’s Health – Rep. Mike Lawler position page Office of Rep. Mike Lawler
  11. [11] Congressman Fitzpatrick: ‘I Don’t Think It’s Wise’ To Advance Restrictive Abortion Bills North Penn Now
  12. [12] Web search · turn 14 #0
  13. [13] Web search · turn 15 #1
  14. [14] Web search · turn 18 #4
  15. [15] Johnson says he does not see national abortion ban next year, even under Trump The Washington Post
  16. [16] Speaker Johnson keeps House lawmakers away, canceling another week's session as shutdown drags AP News
  17. [17] Web search · turn 9 #0
  18. [18] US FDA approves another generic version of abortion pill Reuters
  19. [19] Supreme Court Upholds Access to Abortion Pill in Unanimous Vote Wired

Discussion